Document Detail

Tissue concentrations of gastrointestinal regulatory peptides in the duodenal mucosa in systemic sclerosis.
MedLine Citation:
PMID:  9536389     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: Esophageal hypomotility and abnormalities of intestinal function are important manifestations in systemic sclerosis (SSc), but their pathogenesis is not well understood. Since there is evidence that plasma concentrations of certain gastrointestinal regulatory peptides are increased in SSc, we were interested in examining the peptide concentrations and localization in biopsy specimens from the intestinal mucosa in SSc patients. We studied 12 patients with gastrointestinal disease. METHODS: Levels of corticotrophin-releasing hormone (CRH), motilin, neuropeptide Y (NPY) and peptide YY (PYY) were determined by radioimmunoassay and high-performance liquid chromatography (HPLC), and the occurrence of motilin, PYY, somatostatin, and NPY were studied with immunohistochemistry. RESULTS: Except for the concentrations of CRH, which were increased 2-fold, the tissue concentration of motilin, NPY and PYY were decreased by approximately 50% among patients with esophageal and intestinal dysfunction (group B) compared to patients with impaired esophageal motility alone (group A). In addition, HPLC-characterization of motilin, NPY, and PYY showed a different pattern of fragments among patients in groups A and B. In all patients duodenal motilin, PYY, and somatostatin were localized in the endocrine cells. The distribution and frequency of the cells did not differ among the patients. NPY was localized to neuronal elements; there was no overt difference among the patients with respect to the frequency of NPY-containing nerves. CONCLUSION: This study shows that patients with widespread gastrointestinal disease have lower tissue concentrations of regulatory peptides compared to patients with less widespread disease.
A Akesson; R Ekman; H Prytz; F Sundler
Related Documents :
10063739 - Early changes in esophageal motility after endoscopic variceal sclerotherapy or ligation.
2766899 - Adenocarcinoma arising in barrett's esophagus.
1988269 - Prospective study on prevalence of esophageal chest pain in patients referred on an ele...
21808729 - Comparative evaluation of the reticulocyte hemoglobin content assay when screening for ...
8350489 - A study of pharyngeal symptoms caused by bronchofiberscopy.
3729629 - Systematic esophageal evaluation of patients with noncardiac chest pain.
20853109 - Signal characteristics of focal bone marrow lesions in patients with multiple myeloma u...
9537279 - Exchange transfusion as an adjunct to the treatment of severe falciparum malaria.
15884119 - Genetic association of cytokines polymorphisms with autoimmune hepatitis and primary bi...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Clinical and experimental rheumatology     Volume:  16     ISSN:  0392-856X     ISO Abbreviation:  Clin. Exp. Rheumatol.     Publication Date:    1998 Mar-Apr
Date Detail:
Created Date:  1998-05-14     Completed Date:  1998-05-14     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8308521     Medline TA:  Clin Exp Rheumatol     Country:  ITALY    
Other Details:
Languages:  eng     Pagination:  141-8     Citation Subset:  IM    
Department of Rheumatology, Lund University Hospital, Sweden.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Corticotropin-Releasing Hormone / metabolism
Duodenum / metabolism*
Gastrointestinal Hormones / metabolism*
Intestinal Mucosa / metabolism*
Middle Aged
Motilin / metabolism
Neuropeptide Y / metabolism
Osmolar Concentration
Peptide YY / metabolism
Peptides / metabolism*
Scleroderma, Systemic / metabolism*
Reg. No./Substance:
0/Gastrointestinal Hormones; 0/Neuropeptide Y; 0/Peptides; 106388-42-5/Peptide YY; 52906-92-0/Motilin; 9015-71-8/Corticotropin-Releasing Hormone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Cold-induced coronary Raynaud's phenomenon in patients with systemic sclerosis.
Next Document:  Bindarit prolongs survival and reduces renal damage in NZB/W lupus mice.